Could a blood extract save sight? early trial tests PRP for rare eye diseases

NCT ID NCT07341919

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This pilot study tests whether injections of platelet-rich plasma (PRP) made from a patient's own blood can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants receive three injections over four months, and researchers track changes in visual field and visual acuity over six months. The goal is to see if PRP is safe and might slow vision loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
platelet-rich plasma (PRP)
What this could lead to
If it works, this could point toward a treatment to slow vision loss in certain retinal diseases.
What could go wrong
This is a very early, small pilot study with only 30 participants. It may not show clear benefit, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centro Especializado Retina e Vítreo

    São José do Rio Preto, São Paulo, 15010-100, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.